Palisade Bio, Inc. Share Price
PALIPalisade Bio, Inc. Stock Performance
Open $1.96 | Prev. Close $1.96 | Circuit Range N/A |
Day Range $1.94 - $2.04 | Year Range $0.53 - $2.85 | Volume 2,70,859 |
Average Traded $2.00 |
Palisade Bio, Inc. Share Price Chart
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Palisade Bio, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
28-Apr-26 | $1.96 | $1.97 | +0.00% |
28-Apr-26 | $1.96 | $1.97 | -4.83% |
24-Apr-26 | $2.17 | $2.07 | -4.17% |
23-Apr-26 | $2.30 | $2.16 | -7.30% |
22-Apr-26 | $2.79 | $2.33 | -16.79% |
21-Apr-26 | $2.46 | $2.80 | +12.68% |
20-Apr-26 | $2.34 | $2.48 | +3.54% |